Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma Academic Article uri icon

abstract

  • Patients with early-stage nodal follicular lymphoma (FL) may be rendered free of detectable disease by a diagnostic excisional biopsy. We reviewed the management and outcomes of 48 patients with FL, diagnosed from 2003-2013, treated at a single institution. The primary endpoints were local control (LC) and progression-free survival (PFS).Median age at diagnosis was 54.5 years (range 15-74 years). Forty-seven patients were stage I (97.9%); 15 patients (31.3%) had grade 3 disease. Initial management consisted of observation (12 patients; 25.0%), radiation therapy (RT) alone (12 patients; 25.0%), systemic therapy alone (9 cases; 18.8%), or both (15 patients; 31.3%). Median follow-up was 4.92 years (range 0.5-13.83 years). 4-year PFS and OS were 80.9% and 97.1%, respectively. Patients treated with additional therapy experienced significantly better 4-year LC (100% vs. 81.8%; p = .012) and 4-year PFS (86.7% vs. 63.6%; p = .006).Patients with completely resected limited-stage FL would benefit from therapy beyond excisional biopsy alone.

authors

  • Andraos, Therese Y
  • Ayoub, Zeina
  • Nastoupil, Loretta J
  • Milgrom, Sarah A
  • Pinnix, Chelsea C
  • Ng, Sweet Ping
  • Gunther, Jillian R
  • Fowler, Nathan H
  • Neelapu, Sattva S
  • Samaniego, Felipe
  • Fayad, Luis E
  • Dabaja, Bouthaina S

publication date

  • November 10, 2019

has subject area